2.Flavonoid Myricetin as Potent Anticancer Agent: A Possibility towards Development of Potential Anticancer Nutraceuticals.
Anchal TRIVEDI ; Adria HASAN ; Rumana AHMAD ; Sahabjada SIDDIQUI ; Aditi SRIVASTAVA ; Aparna MISRA ; Snober S MIR
Chinese journal of integrative medicine 2024;30(1):75-84
Good nutrition plays a crucial role in maintaining a balanced lifestyle. The beneficial effects of nutrition have been found to counteract nutritional disturbances with the expanded use of nutraceuticals to treat and manage cardiovascular diseases, cancer, and other developmental defects over the last decade. Flavonoids are found abundantly in plant-derived foods such as fruits, vegetables, tea, cocoa, and wine. Fruits and vegetables contain phytochemicals like flavonoids, phenolics, alkaloids, saponins, and terpenoids. Flavonoids can act as anti-inflammatory, anti-allergic, anti-microbial (antibacterial, antifungal, and antiviral) antioxidant, anti-cancer, and anti-diarrheal agents. Flavonoids are also reported to upregulate apoptotic activity in several cancers such as hepatic, pancreatic, breast, esophageal, and colon. Myricetin is a flavonol which is naturally present in fruits and vegetables and has shown possible nutraceutical value. Myricetin has been portrayed as a potent nutraceutical that may protect against cancer. The focus of the present review is to present an updated account of studies demonstrating the anticancer potential of myricetin and the molecular mechanisms involved therein. A better understanding of the molecular mechanism(s) underlying its anticancer activity would eventually help in its development as a novel anticancer nutraceutical having minimal side effects.
Humans
;
Flavonoids/chemistry*
;
Antineoplastic Agents/chemistry*
;
Dietary Supplements
;
Antioxidants/pharmacology*
;
Neoplasms/drug therapy*
3.Structure-activity relationship of Lycium barbarum polysaccharides.
Xiao-Fei LIANG ; Fang ZHANG ; Yin-Xiu JIANG ; Meng-Qiu LIU ; Sheng GUO ; Da-Wei QIAN ; Jin-Ao DUAN
China Journal of Chinese Materia Medica 2023;48(9):2387-2395
As a traditional Chinese herb and functional food, the fruits of Lycium barbarum has been widely used for thousands of years in China. L. barbarum polysaccharides(LBPs) are predominant active components, which have immunomodulatory, antioxidant, hypoglycemic, neuroprotective, anti-tumor, and prebiotic activities. The molecular weight, monosaccharide composition, glycosidic bond, branching degree, protein content, chemical modification, and spatial structure of LBPs are closely related to their biological activity. Based on the previous studies of this research team, this paper systematically combed and integrated the research progress of structure, function, and structure-activity relationship of LBPs. At the same time, some problems restricting the clarification of the structure-activity relationship of LBPs were considered and prospected, hoping to provide references for the high value utilization of LBPs and in-depth exploration of their health value.
Lycium/chemistry*
;
Drugs, Chinese Herbal/chemistry*
;
Structure-Activity Relationship
;
Antioxidants/pharmacology*
;
Antineoplastic Agents
;
Polysaccharides/chemistry*
4.SMILESynergy: Anticancer drug synergy prediction based on Transformer pre-trained model.
Liqiang ZHANG ; Yufang QIN ; Ming CHEN
Journal of Biomedical Engineering 2023;40(3):544-551
The synergistic effect of drug combinations can solve the problem of acquired resistance to single drug therapy and has great potential for the treatment of complex diseases such as cancer. In this study, to explore the impact of interactions between different drug molecules on the effect of anticancer drugs, we proposed a Transformer-based deep learning prediction model-SMILESynergy. First, the drug text data-simplified molecular input line entry system (SMILES) were used to represent the drug molecules, and drug molecule isomers were generated through SMILES Enumeration for data augmentation. Then, the attention mechanism in the Transformer was used to encode and decode the drug molecules after data augmentation, and finally, a multi-layer perceptron (MLP) was connected to obtain the synergy value of the drugs. Experimental results showed that our model had a mean squared error of 51.34 in regression analysis, an accuracy of 0.97 in classification analysis, and better predictive performance than the DeepSynergy and MulinputSynergy models. SMILESynergy offers improved predictive performance to assist researchers in rapidly screening optimal drug combinations to improve cancer treatment outcomes.
Electric Power Supplies
;
Neural Networks, Computer
;
Antineoplastic Agents/pharmacology*
5.Study on the Relationship between Integrin 2A and Drug Resistance in Chronic Myeloid Leukemia.
Nai-Qin ZHAO ; Cheng-Yun PAN ; Tian-Zhuo ZHANG ; Ping LIU ; Tian-Zhen HU ; Qin SHANG ; Hong LUO ; Qin FANG ; Ji-Shi WANG
Journal of Experimental Hematology 2023;31(1):8-16
OBJECTIVE:
To explore the expression pattern and clinical significance of Integral membrane protein 2A(ITM2A) in drug resistant patients with chronic myeloid leukemia (CML).
METHODS:
The expression of ITM2A in CML was evaluated by qRT-PCR, Western blot and immunocytochemistry. In order to understand the possible biological effects of ITM2A, apoptosis, cell cycle and myeloid differentiation antigen expression of CML cells were detected by flow cytometry after over-expression of ITM2A. The nuderlying molecular mechanism of its biological effect was explored.
RESULTS:
The expression of ITM2A in bone marrow of CML resistant patients was significantly lower than that of sensitive patients and healthy donors(P<0.05). The CML resistant strain cell K562R was successfully constructed in vitro. The expression of ITM2A in the resistant strain was significantly lower than that in the sensitive strain(P<0.05). Overexpression of ITM2A in K562R cells increased the sensitivity of K562R cells to imatinib and blocked the cell cycle in G2 phase(P<0.05), but did not affect myeloid differentiation. Mechanistically, up-regulation of ITM2A reduced phosphorylation in ERK signaling (P<0.05).
CONCLUSION
The expression of ITM2A was low in patients with drug resistance of CML, and the low expression of ITM2A may be the key factor of imatinib resistance in CML.
Humans
;
Antineoplastic Agents/pharmacology*
;
Apoptosis
;
Drug Resistance, Neoplasm
;
Imatinib Mesylate/therapeutic use*
;
K562 Cells
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*
;
Signal Transduction
6.Therapeutic Properties of Flavonoids in Treatment of Cancer through Autophagic Modulation: A Systematic Review.
Guilherme Vinício DE SOUSA SILVA ; Ana Luiza Vieira Ferreira Guimarães LOPES ; Isis Carolina VIALI ; Lucas Zannini Medeiros LIMA ; Matheus Ribeiro BIZUTI ; Fabiana Brum HAAG ; Débora TAVARES DE RESENDE E SILVA
Chinese journal of integrative medicine 2023;29(3):268-279
Cancers have high morbidity and mortality rates worldwide. Current anticancer therapies have demonstrated specific signaling pathways as a target in the involvement of carcinogenesis. Autophagy is a quality control system for proteins and plays a fundamental role in cancer carcinogenesis, exerting an anticarcinogenic role in normal cells and can inhibit the transformation of malignant cells. Therefore, drugs aimed at autophagy can function as antitumor agents. Flavonoids are a class of polyphenolic secondary metabolites commonly found in plants and, consequently, consumed in diets. In this review, the systematic search strategy was used, which included the search for descriptors "flavonoids" AND "mTOR pathway" AND "cancer" AND "autophagy", in the electronic databases of PubMed, Cochrane Library, Web of Science and Scopus, from January 2011 to January 2021. The current literature demonstrates that flavonoids have anticarcinogenic properties, including inhibition of cell proliferation, induction of apoptosis, autophagy, necrosis, cell cycle arrest, senescence, impaired cell migration, invasion, tumor angiogenesis and reduced resistance to multiple drugs in tumor cells. We demonstrate the available evidence on the roles of flavonoids and autophagy in cancer progression and inhibition. (Registration No. CRD42021243071 at PROSPERO).
Humans
;
Flavonoids/pharmacology*
;
Neoplasms
;
Antineoplastic Agents/pharmacology*
;
Signal Transduction
;
Apoptosis
;
Cell Proliferation
;
Carcinogenesis
;
Cell Line, Tumor
7.TRPV1 participates in the protective effect of propolis on colonic tissue of ulcerative colitis.
Jing WANG ; Zhen QIAN ; Taiyu LU ; Ruirui LI ; Hui LI ; Hao ZHANG ; Li SUN ; Haihua WANG
Journal of Central South University(Medical Sciences) 2023;48(2):182-190
OBJECTIVES:
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) mainly characterized by inflammation, ulceration and erosion of colonic mucosa and submucosa. Transient receptor potential vanilloid 1 (TRPV1) is an important mediator of visceral pain and inflammatory bowel disease. This study aims to investigate the protective effect of water soluble propolis (WSP) on UC colon inflammatory tissue and the role of TRPV1.
METHODS:
Male SD rats were randomly divided into 6 groups (n=8): a normal control (NC) group, an ulcerative colitis model (UC) group, a low-WSP (L-WSP) group, a medium-WSP (M-WSP) group, a high-WSP (H-WSP) group, and a salazosulfapyridine (SASP) group. The rats in the NC group drank water freely, and the other groups drank 4% dextran sulfate sodium (DSS) solution freely for 7 d to replicate the ulcerative colitis model. Based on the successful replication of the UC, the L-WSP, M-WSP, and H-WSP groups were given 50, 100, and 200 mg/kg of water-soluble propolis by gavage for 7 d, and the SASP group was given 100 mg/kg of sulfasalazine by gavage for 7 d. The body weight of rats in each group was measured at the same time every day, the fecal traits and occult blood were observed to record the disease activity index (DAI). After intragastric administration, the animals were sacrificed after fasted 24 h. Serum and colonic tissue were collected, and the changes of MDA, IL-6 and TNF-α were detected. The pathological changes of colon tissues were observed by HE staining, and the expression of TRPV1 in colon tissues was observed by Western blotting, immunohistochemistry, and immunofluorescence.
RESULTS:
The animals in each group that drank DSS freely showed symptoms such as weight loss, decreased appetite, depressed state, and hematochezia, indicating that the model was successfully established. Compared with the NC group, DAI scores of other groups were increased (all P<0.05). MDA, IL-6, TNF-α in serum and colon tissues of the UC group were increased compared with the NC group (all P<0.01), and they were decreased after WSP and SASP treatment (all P<0.01). The results of showed that the colon tissue structure was obviously broken and inflammatory infiltration in the UC group, while the H-WSP group and the SASP group significantly improved the colon tissue and alleviated inflammatory infiltration. The expression of TRPV1 in colon tissues in the UC group was increased compared with the NC group (all P<0.01), and it was decreased after WSP and SASP treatment.
CONCLUSIONS
WSP can alleviate the inflammatory state of ulcerative colitis induced by DSS, which might be related to the inhibition of inflammatory factors release, and down-regulation or desensitization of TRPV1.
Animals
;
Male
;
Rats
;
Antineoplastic Agents/therapeutic use*
;
Colitis, Ulcerative/chemically induced*
;
Colon/pathology*
;
Disease Models, Animal
;
Interleukin-6/pharmacology*
;
Propolis/therapeutic use*
;
Rats, Sprague-Dawley
;
Sulfasalazine/therapeutic use*
;
TRPV Cation Channels
;
Tumor Necrosis Factor-alpha/pharmacology*
8.Disulfiram enhances the antitumor activity of cisplatin by inhibiting the Fanconi anemia repair pathway.
Meng YUAN ; Qian WU ; Mingyang ZHANG ; Minshan LAI ; Wenbo CHEN ; Jianfeng YANG ; Li JIANG ; Ji CAO
Journal of Zhejiang University. Science. B 2023;24(3):207-220
A series of chemotherapeutic drugs that induce DNA damage, such as cisplatin (DDP), are standard clinical treatments for ovarian cancer, testicular cancer, and other diseases that lack effective targeted drug therapy. Drug resistance is one of the main factors limiting their application. Sensitizers can overcome the drug resistance of tumor cells, thereby enhancing the antitumor activity of chemotherapeutic drugs. In this study, we aimed to identify marketable drugs that could be potential chemotherapy sensitizers and explore the underlying mechanisms. We found that the alcohol withdrawal drug disulfiram (DSF) could significantly enhance the antitumor activity of DDP. JC-1 staining, propidium iodide (PI) staining, and western blotting confirmed that the combination of DSF and DDP could enhance the apoptosis of tumor cells. Subsequent RNA sequencing combined with Gene Set Enrichment Analysis (GSEA) pathway enrichment analysis and cell biology studies such as immunofluorescence suggested an underlying mechanism: DSF makes cells more vulnerable to DNA damage by inhibiting the Fanconi anemia (FA) repair pathway, exerting a sensitizing effect to DNA damaging agents including platinum chemotherapy drugs. Thus, our study illustrated the potential mechanism of action of DSF in enhancing the antitumor effect of DDP. This might provide an effective and safe solution for combating DDP resistance in clinical treatment.
Female
;
Male
;
Humans
;
Cisplatin/pharmacology*
;
Disulfiram/pharmacology*
;
Testicular Neoplasms/drug therapy*
;
Fanconi Anemia/drug therapy*
;
Alcoholism/drug therapy*
;
Drug Resistance, Neoplasm
;
Cell Line, Tumor
;
Substance Withdrawal Syndrome/drug therapy*
;
Apoptosis
;
Antineoplastic Agents/therapeutic use*
;
Cell Proliferation
9.In vitro and in vivo anticancer potential and molecular targets of the new colchicine analog IIIM-067.
Sumera MALIK ; Mubashir J MINTOO ; Chilakala Nagarjuna REDDY ; Rajesh KUMAR ; Pankul KOTWAL ; Sandip B BHARATE ; Utpal NANDI ; Dilip M MONDHE ; Sanket K SHUKLA
Journal of Integrative Medicine 2023;21(1):62-76
OBJECTIVE:
The current study evaluated various new colchicine analogs for their anticancer activity and to study the primary mechanism of apoptosis and in vivo antitumor activity of the analogs with selective anticancer properties and minimal toxicity to normal cells.
METHODS:
Sulforhodamine B (SRB) assay was used to screen various colchicine analogs for their in vitro cytotoxicity. The effect of N-[(7S)-1,2,3-trimethoxy-9-oxo-10-(pyrrolidine-1-yl)5,6,7,9-tetrahydrobenzo[a] heptalene-7-yl] acetamide (IIIM-067) on clonogenicity, apoptotic induction, and invasiveness of A549 cells was determined using a clonogenic assay, scratch assay, and staining with 4',6-diamidino-2-phenylindole (DAPI) and annexin V/propidium iodide. Mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) levels were observed using fluorescence microscopy. Western blot analysis was used to quantify expression of proteins involved in apoptosis, cell cycle, and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling. Pharmacokinetic and in vivo efficacy studies against Ehrlich ascites carcinoma (EAC) and Ehrlich solid tumor models were conducted using Swiss albino mice.
RESULTS:
IIIM-067 showed potent cytotoxicity and better selectivity than all other colchicine analogs screened in this study. The selective activity of IIIM-067 toward A549 cells was higher among other cancer cell lines, with a selectivity index (SI) value of 2.28. IIIM-067 demonstrated concentration- and time-dependent cytotoxicity against A549 cells with half-maximal inhibitory concentration values of 0.207, 0.150 and 0.106 μmol/L at 24, 48 and 72 h, respectively. It also had reduced toxicity to normal cells (SI > 1) than the parent compound colchicine (SI = 1). IIIM-067 reduced the clonogenic ability of A549 cells in a dose-dependent manner. IIIM-067 enhanced ROS production from 24.6% at 0.05 μmol/L to 82.1% at 0.4 μmol/L and substantially decreased the MMP (100% in control to 5.6% at 0.4 μmol/L). The annexin V-FITC assay demonstrated 78% apoptosis at 0.4 μmol/L. IIIM-067 significantly (P < 0.5) induced the expression of various intrinsic apoptotic pathway proteins, and it differentially regulated the PI3K/AKT/mTOR signaling pathway. Furthermore, IIIM-067 exhibited remarkable in vivo anticancer activity against the murine EAC model, with tumor growth inhibition (TGI) of 67.0% at a dose of 6 mg/kg (i.p.) and a reduced mortality compared to colchicine. IIIM-067 also effectively inhibited the tumor growth in the murine solid tumor model with TGI rates of 48.10%, 55.68% and 44.00% at doses of 5 mg/kg (i.p.), 6 mg/kg (i.p.) and 7 mg/kg (p.o.), respectively.
CONCLUSION
IIIM-067 exhibited significant anticancer activity with reduced toxicity both in vitro and in vivo and is a promising anticancer candidate. However, further studies are required in clinical settings to fully understand its potential.
Animals
;
Mice
;
Proto-Oncogene Proteins c-akt/metabolism*
;
Antineoplastic Agents, Phytogenic/pharmacology*
;
Phosphatidylinositol 3-Kinases/metabolism*
;
Reactive Oxygen Species/metabolism*
;
TOR Serine-Threonine Kinases/metabolism*
;
Colchicine/pharmacology*
;
Apoptosis
;
Cell Line, Tumor
;
Cell Proliferation
;
Mammals/metabolism*
10.Astragaloside in cancer chemoprevention and therapy.
Yaning WANG ; Zhuo ZHANG ; Zhaohua CHENG ; Wei XIE ; Hanjiao QIN ; Jiyao SHENG
Chinese Medical Journal 2023;136(10):1144-1154
Tumor chemoprevention and treatment are two approaches aimed at improving the survival of patients with cancers. An ideal anti-tumor drug is that which not only kills tumor cells but also alleviates tumor-causing risk factors, such as precancerous lesions, and prevents tumor recurrence. Chinese herbal monomers are considered to be ideal treatment agents due to their multi-target effects. Astragaloside has been shown to possess tumor chemoprevention, direct anti-tumor, and chemotherapeutic drug sensitization effects. In this paper, we review the effects of astragaloside on tumor prevention and treatment and provide directions for further research.
Humans
;
Chemoprevention
;
Antineoplastic Agents
;
Neoplasms/prevention & control*
;
Saponins/pharmacology*
;
Triterpenes/pharmacology*

Result Analysis
Print
Save
E-mail